Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 12/20 | 0.78 |
| ▸ | BCHE | P06276 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | XBP1 | P17861 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5714804 | 0.95 | LIPE (0.70) | LIPEBCHESMN1; SMN2HPGDMAPT | |
| SCHEMBL5715024 | 0.94 | LIPE (0.69) | LIPEBCHESMN1; SMN2HPGDMAPT | |
| SCHEMBL5714657 | 0.94 | LIPE (0.69) | LIPEBCHESMN1; SMN2HPGDMAPT | |
| SCHEMBL5714412 | 0.94 | LIPE (0.69) | LIPEBCHESMN1; SMN2HPGDMAPT | |
| SCHEMBL5715572 | 0.93 | LIPE (0.68) | LIPEBCHESMN1; SMN2HPGDMAPT | |
| SCHEMBL5649923 | 0.91 | LIPE (0.70) | LIPEBCHESMN1; SMN2MAPTHTT | |
| SCHEMBL5714844 | 0.91 | LIPE (0.64) | LIPEBCHESMN1; SMN2HPGDMAPT | |
| SCHEMBL5650091 | 0.89 | LIPE (0.70) | LIPEBCHESMN1; SMN2MAPTHTT | |
| SCHEMBL5648808 | 0.87 | LIPE (0.74) | LIPEBCHESMN1; SMN2MAPTHTT | |
| SCHEMBL5648434 | 0.87 | MAPT (0.78) | LIPEBCHESMN1; SMN2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160819-A1 | Substitued piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1636189-A1 | 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | claimed |
| WO-2004111007-A1 | 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | claimed |
| EP-1636189-A1 | 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111007-A1 | 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160819-A1 | Substitued piperazine carbamates | LIPE, PNLIP, LIPC | LIPE 1/4885BCHE 200/4885SMN1; SMN2 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.